<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02836782</url>
  </required_header>
  <id_info>
    <org_study_id>Prot.7768/16 ID 1086</org_study_id>
    <nct_id>NCT02836782</nct_id>
  </id_info>
  <brief_title>HIV-DNA Dynamics in HIV Monoinfected or HIV/HCV Coinfected Patients</brief_title>
  <acronym>ViDyMoCo</acronym>
  <official_title>Dynamics of Viral Reservoir in HIV-positive Patients With or Without HCV Coinfection in the Era of Direct-acting Antiviral and Antiretroviral Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      New markers of viral activity are now under investigation. Aim of the study is to investigate
      the efficacy of new antiretroviral drugs by monitoring HIV-DNA dynamics in HIV-positive
      population. In HIV/HCV coinfected population, the study of HIV reservoir dynamics and the
      analysis of the prevalence of HCV resistance-associated mutations will help clinicians to
      improve the management of coinfected patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      New markers of viral activity are now under investigation. Besides HIV-RNA and CD4 cells
      count, HIV-DNA is an emerging marker of viral reservoir, that seems to be associated with the
      risk of HIV-related diseases, especially in HCV coinfected patients. New antiretroviral
      drugs, particularly integrase inhibitors, are expected to decrease residual viremia and,
      consequently, viral reservoir. Monitoring of HIV-DNA dynamics during antiretroviral treatment
      could lead to a better management of HIV infected population.

      Also, the role of HCV in influencing HIV natural history requires careful monitoring. In
      particular, with a broader use of direct acting antiretroviral, the analysis of prevalence of
      HCV resistance associated mutation will be more and more important to manage patients with
      treatment failure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Percentage of HIV-positive patients with a significant HIV-DNA decay after 3 years from a new antiretroviral regimen start</measure>
    <time_frame>up to 144 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of HIV/HCV coinfected patients with a significant HIV-DNA decay after 3 years from the enrollment</measure>
    <time_frame>up to 144 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HIV-DNA level during HCV antiviral therapy with DAA in HIV/HCV coinfected patients</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of HCV resistance-associated variants and their relation with HIV-DNA levels in HIV/HCV coinfected patients, treated or not treated for HCV.</measure>
    <time_frame>up to 144 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the prevalence of HCV resistance-associated variants in HIV/HCV coinfected population versus HCV monoinfected population</measure>
    <time_frame>up to 144 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Naive patients</arm_group_label>
    <description>Patients who begin their first antiretroviral regimen. Blood sample withdrawal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experienced patients</arm_group_label>
    <description>Patients with a history of antiretroviral treatment, switching to a new regimen.
Blood sample withdrawal</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample withdrawal</intervention_name>
    <description>Blood withdrawal for HIV-DNA or HCV resistance test</description>
    <arm_group_label>Naive patients</arm_group_label>
    <arm_group_label>Experienced patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persons â‰¥ 18 years-old;

          -  Signing an informed consent to study participation and data treatment;

          -  HIV-positive patients, beginning a new antiretroviral treatment patients or with
             clinically relevant events;

          -  HCV-positive patients beginning an antiviral treatment with DAA.

        Exclusion Criteria:

          -  Patient's deny

          -  Clinical contraindications to blood sample withdrawal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simona Di Giambenedetto, Researcher</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University of Sacred Heart</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simona Di Giambenedetto, Researcher</last_name>
    <phone>0630155366</phone>
    <email>simona.digiambenedetto@unicatt.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Catholic University of Sacred Heart</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Di Giambenedetto, Researcher</last_name>
      <phone>00390630155366</phone>
      <email>simona.digiambenedetto@unicatt.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Kostrikis LG, Touloumi G, Karanicolas R, Pantazis N, Anastassopoulou C, Karafoulidou A, Goedert JJ, Hatzakis A; Multicenter Hemophilia Cohort Study Group. Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. J Virol. 2002 Oct;76(20):10099-108.</citation>
    <PMID>12239284</PMID>
  </reference>
  <reference>
    <citation>Shiramizu B, Paul R, Williams A, Shikuma C, Watters M, Grove J, Valcour V. HIV proviral DNA associated with decreased neuropsychological function. J Neuropsychiatry Clin Neurosci. 2007 Spring;19(2):157-63.</citation>
    <PMID>17431062</PMID>
  </reference>
  <reference>
    <citation>Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016 Jan;36 Suppl 1:47-57. doi: 10.1111/liv.13027. Review.</citation>
    <PMID>26725897</PMID>
  </reference>
  <reference>
    <citation>Bagaglio S, Uberti-Foppa C, Messina E, Merli M, Hasson H, Andolina A, Galli A, Lazzarin A, Morsica G. Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients. Clin Microbiol Infect. 2016 Apr;22(4):386.e1-386.e3. doi: 10.1016/j.cmi.2015.12.007. Epub 2015 Dec 17.</citation>
    <PMID>26706617</PMID>
  </reference>
  <reference>
    <citation>Di Maio VC, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, Micheli V, Bellocchi MC, Antonucci FP, Bertoli A, Lenci I, Milana M, Gianserra L, Melis M, Di Biagio A, Sarrecchia C, Sarmati L, Landonio S, Francioso S, Lambiase L, Nicolini LA, Marenco S, Nosotti L, Giannelli V, Siciliano M, Romagnoli D, Pellicelli A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Taliani G, Mastroianni C, Vespasiani-Gentilucci U, Romano M, Morisco F, Gasbarrini A, Vullo V, Bruno S, Baiguera C, Pasquazzi C, Tisone G, Picciotto A, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. J Antimicrob Chemother. 2016 Mar;71(3):739-50. doi: 10.1093/jac/dkv403. Epub 2015 Dec 17.</citation>
    <PMID>26679249</PMID>
  </reference>
  <reference>
    <citation>AASLD/IDSA/IAS-USA RETREATMENT OF PERSONS IN WHOM PRIOR THERAPY HAS FAILED. Recommendations for testing, managing, and treating hepatitis C. date accessed 5.01. 2015.</citation>
  </reference>
  <reference>
    <citation>Fourati S, Pawlotsky JM. Virologic Tools for HCV Drug Resistance Testing. Viruses. 2015 Dec 4;7(12):6346-59. doi: 10.3390/v7122941. Review.</citation>
    <PMID>26690198</PMID>
  </reference>
  <reference>
    <citation>Perales C, Quer J, Gregori J, Esteban JI, Domingo E. Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications. Viruses. 2015 Nov 6;7(11):5746-66. doi: 10.3390/v7112902. Review.</citation>
    <PMID>26561827</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2016</study_first_submitted>
  <study_first_submitted_qc>July 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <last_update_submitted>July 14, 2016</last_update_submitted>
  <last_update_submitted_qc>July 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Simona Di Giambenedetto</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>HIV/HCV</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <keyword>HIV-DNA</keyword>
  <keyword>Direct acting antiviral</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

